Suppliers and packagers for generic pharmaceutical drug: FOSFOMYCIN TROMETHAMINE

FOSFOMYCIN TROMETHAMINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alkem Labs Ltd	FOSFOMYCIN TROMETHAMINE	fosfomycin tromethamine	FOR SOLUTION;ORAL	214554	ANDA	A-S Medication Solutions	50090-6130-0	1 PACKET in 1 CARTON (50090-6130-0) / 1 GRANULE, FOR SOLUTION in 1 PACKET	2021-10-22
Alkem Labs Ltd	FOSFOMYCIN TROMETHAMINE	fosfomycin tromethamine	FOR SOLUTION;ORAL	214554	ANDA	Ascend Laboratories, LLC	67877-749-57	1 PACKET in 1 CARTON (67877-749-57) / 1 GRANULE, FOR SOLUTION in 1 PACKET	2021-10-22
Alkem Labs Ltd	FOSFOMYCIN TROMETHAMINE	fosfomycin tromethamine	FOR SOLUTION;ORAL	214554	ANDA	Kesin Pharma Corporation	81033-024-11	1 PACKET in 1 CARTON (81033-024-11) / 1 GRANULE, FOR SOLUTION in 1 PACKET (81033-024-03)	2021-10-22
Amneal	FOSFOMYCIN TROMETHAMINE	fosfomycin tromethamine	FOR SOLUTION;ORAL	216600	ANDA	Amneal Pharmaceuticals NY LLC	60219-3955-1	1 PACKET in 1 CARTON (60219-3955-1) / 1 GRANULE, FOR SOLUTION in 1 PACKET (60219-3955-3)	2024-04-02

Fosfomycin Tromethamine Suppliers Analysis

Last updated: February 19, 2026

This report analyzes the global supplier landscape for fosfomycin tromethamine, a key antibiotic. It details manufacturing capabilities, regulatory standing, and strategic considerations for pharmaceutical companies. The analysis identifies major players and assesses their capacity to meet demand.

What is Fosfomycin Tromethamine and its Market Significance?

Fosfomycin tromethamine is the tromethamine salt of fosfomycin, a broad-spectrum antibiotic effective against a range of Gram-positive and Gram-negative bacteria. It functions by inhibiting the enzyme MurA, which is crucial for bacterial cell wall synthesis. This mechanism of action makes it valuable in treating complicated urinary tract infections (cUTIs), both complicated and uncomplicated cystitis, and pneumonia.

The growing prevalence of antibiotic-resistant bacteria, including extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae, has renewed interest in fosfomycin as a therapeutic option. Its efficacy against multidrug-resistant (MDR) pathogens positions it as a critical tool in the antimicrobial stewardship arsenal. The global fosfomycin tromethamine market is driven by increasing infection rates, a rise in hospital-acquired infections, and the demand for effective treatments for UTIs, which are among the most common bacterial infections globally [1].

The market is characterized by a limited number of active pharmaceutical ingredient (API) manufacturers, with production concentrated in specific regions due to specialized manufacturing requirements and regulatory hurdles. Pricing is influenced by production costs, raw material availability, and the stringency of quality control and regulatory compliance.

Who are the Key Global Manufacturers of Fosfomycin Tromethamine API?

The production of fosfomycin tromethamine API is a complex process requiring specialized facilities and adherence to stringent Good Manufacturing Practices (GMP). Several companies globally are recognized for their expertise in this area.

Key API manufacturers include:

• Zhejiang Pharmaceutical Co., Ltd. (ZMC): A major Chinese pharmaceutical company with extensive experience in antibiotic production. ZMC has a significant global market share for fosfomycin and its salts. Their production capacity is considered substantial, catering to both domestic and international markets. They hold certifications such as US FDA, EDQM, and WHO GMP, enabling supply to regulated markets [2].
• Fosfomycin Pharmaceutical Co., Ltd. (Subsidiary of ZMC): Often operating under the ZMC umbrella, this entity specifically focuses on fosfomycin production, ensuring dedicated resources and streamlined manufacturing processes.
• Union Brothers Chemical Co., Ltd. Located in China, this company is also a notable producer of fosfomycin tromethamine. They emphasize quality control and regulatory compliance in their manufacturing operations.
• Sanofi S.A. While Sanofi is a major pharmaceutical company, their role is primarily as a brand-name marketer and distributor of finished dosage forms (e.g., Monurol®). They may source their API from dedicated manufacturers rather than producing it in-house on a large commercial scale for external sale. However, historically, Sanofi played a significant role in the development and initial commercialization of fosfomycin.
• Patheon (now part of Thermo Fisher Scientific): As a Contract Development and Manufacturing Organization (CDMO), Patheon has the capability to manufacture APIs, including fosfomycin tromethamine, for pharmaceutical clients. Their involvement is typically project-specific and depends on client demand and manufacturing agreements.

Table 1: Selected Fosfomycin Tromethamine API Manufacturers and Key Attributes

Manufacturer	Country of Origin	Key Certifications (Examples)	Primary Focus
Zhejiang Pharmaceutical Co., Ltd.	China	US FDA, EDQM, WHO GMP	Large-scale API production, global supply
Fosfomycin Pharmaceutical Co., Ltd.	China	US FDA, EDQM, WHO GMP	Dedicated fosfomycin salt manufacturing
Union Brothers Chemical Co., Ltd.	China	ISO, GMP	API manufacturing, quality assurance
Patheon (Thermo Fisher Scientific)	Global	Various (client-dependent)	CDMO services, custom API manufacturing

What are the Regulatory Considerations for Fosfomycin Tromethamine?

Navigating the regulatory landscape is critical for API suppliers and pharmaceutical companies sourcing fosfomycin tromethamine. Compliance with international standards ensures product quality, safety, and efficacy.

Key regulatory aspects include:

• Good Manufacturing Practices (GMP): Manufacturers must adhere to GMP guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) through the European Directorate for the Quality of Medicines & HealthCare (EDQM), and the World Health Organization (WHO). These guidelines cover all aspects of production, including facility design, equipment, personnel training, quality control, and documentation.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies like the FDA. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. Pharmaceutical companies can reference a DMF in their drug product applications, allowing regulatory agencies to review the API information without the manufacturer disclosing proprietary details to the drug product applicant.
• Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP): Issued by the EDQM, a CEP certifies that an API complies with the requirements of the European Pharmacopoeia. This facilitates the marketing authorization process for drug products in Europe and other regions recognizing CEPs.
• Inspections and Audits: Regulatory agencies conduct routine inspections of manufacturing facilities to ensure ongoing compliance with GMP. Pharmaceutical companies also conduct their own supplier audits to verify quality systems and manufacturing capabilities.
• Impurity Profiles: Manufacturers must rigorously control and characterize impurities present in the API. Regulatory agencies require detailed impurity profiles and established acceptance criteria for each impurity.

Table 2: Key Regulatory Bodies and Their Role in Fosfomycin Tromethamine Supply

Regulatory Body	Region/Scope	Key Requirements/Documentation
US FDA	United States	GMP compliance, DMF submission, facility inspections
EMA/EDQM	Europe	GMP compliance, CEP issuance, pharmacopoeial standards
WHO	Global	WHO GMP certification, Prequalification program

What are the Supply Chain Challenges and Risks?

The supply chain for fosfomycin tromethamine API presents several challenges and risks that pharmaceutical companies must manage.

These include:

• Geographic Concentration of Manufacturing: A significant portion of fosfomycin tromethamine API production is concentrated in China. This concentration creates a risk of supply disruption due to geopolitical events, natural disasters, or localized regulatory enforcement.
• Raw Material Sourcing: The synthesis of fosfomycin involves specific precursors and reagents. Fluctuations in the availability or price of these raw materials can impact API production costs and lead times. Supply chain disruptions for key intermediates can have a cascading effect.
• Quality Control and Consistency: Ensuring consistent quality across batches and from different manufacturers is paramount. Deviations in API quality can lead to rejected batches, product recalls, and regulatory non-compliance.
• Lead Times: The manufacturing process for APIs can be lengthy, involving multiple synthesis steps and purification. This results in significant lead times from order placement to delivery, requiring careful inventory management and forecasting.
• Intellectual Property and Generic Competition: While the patent for fosfomycin itself has long expired, specific manufacturing processes or polymorphs may be subject to patent protection. Generic manufacturers must navigate these IP landscapes, and the market can see intense price competition.
• Regulatory Changes: Evolving regulatory requirements or stricter enforcement can necessitate significant investment in facility upgrades or process changes for API manufacturers, potentially impacting supply continuity and cost.

What are the Strategic Sourcing and Partnership Opportunities?

For pharmaceutical companies developing or marketing fosfomycin tromethamine-based products, strategic sourcing and robust supplier partnerships are essential.

Key opportunities include:

• Dual Sourcing Strategy: To mitigate supply chain risks, pharmaceutical companies should consider qualifying and engaging with multiple API suppliers. This diversification ensures continuity of supply in case of issues with a primary supplier. For example, companies might dual-source from both ZMC and Union Brothers Chemical Co., Ltd. to reduce reliance on a single entity.
• Long-Term Supply Agreements: Establishing long-term contracts with preferred API suppliers provides price stability, guaranteed capacity, and a commitment from the supplier to maintain quality standards. These agreements should include clear terms regarding quality, delivery schedules, and change control.
• CDMO Partnerships: Leveraging Contract Development and Manufacturing Organizations (CDMOs) can provide flexibility, specialized expertise, and access to manufacturing capacity without the need for direct capital investment in API production facilities. Companies like Patheon can offer services from process development through commercial manufacturing.
• Supplier Audits and Quality Management: Implementing a rigorous supplier qualification and ongoing monitoring program is crucial. This includes conducting thorough audits of potential and existing suppliers' quality systems, manufacturing facilities, and regulatory compliance records.
• Geographic Diversification of Suppliers (where feasible): While challenging due to the current manufacturing landscape, exploring suppliers in different geographic regions can further de-risk the supply chain. This might involve identifying emerging manufacturers or encouraging established players to expand their footprint.
• Collaboration on Process Improvement: Partnering with API manufacturers on process optimization can lead to improved yields, reduced costs, and enhanced sustainability. This collaborative approach fosters stronger supplier relationships and can result in competitive advantages.

Key Takeaways

The global supply of fosfomycin tromethamine API is characterized by a limited number of established manufacturers, primarily located in China. Zhejiang Pharmaceutical Co., Ltd. (ZMC) and its associated entities are dominant players, possessing significant production capacity and holding key international regulatory certifications. Regulatory compliance, particularly adherence to GMP and the submission of comprehensive DMFs and CEPs, is non-negotiable for suppliers serving regulated markets like the US and Europe.

Supply chain risks include geographic concentration, raw material volatility, and the need for consistent quality control. Pharmaceutical companies must adopt a strategic sourcing approach, prioritizing dual sourcing, long-term supply agreements, and robust supplier audits to ensure uninterrupted access to high-quality API. Leveraging CDMOs offers an alternative for flexible manufacturing solutions.

Frequently Asked Questions

1. What is the primary mechanism of action for fosfomycin tromethamine? Fosfomycin tromethamine inhibits bacterial cell wall synthesis by irreversibly inactivating the enzyme MurA (UDP-N-acetylglucosamine enolpyruvyltransferase), which is essential for peptidoglycan biosynthesis.

2. Which regions are the leading exporters of fosfomycin tromethamine API? The majority of fosfomycin tromethamine API is exported from China.

3. What are the typical lead times for ordering fosfomycin tromethamine API from a major manufacturer? Lead times can vary significantly but generally range from 3 to 6 months, depending on the manufacturer's current production schedule, order volume, and complexity of the supply chain for raw materials.

4. Are there any significant patent expiries relevant to fosfomycin tromethamine manufacturing processes? The fundamental patent for fosfomycin itself has long expired. However, patents may exist for specific manufacturing processes, crystalline forms (polymorphs), or novel formulations, which generic manufacturers must navigate.

5. What are the most common therapeutic indications for drugs containing fosfomycin tromethamine? Fosfomycin tromethamine is primarily indicated for the treatment of uncomplicated urinary tract infections (cystitis) and as an alternative treatment for complicated urinary tract infections and acute bacterial prostatitis. It is also used for surgical prophylaxis.

Citations

[1] Smith, J. L., & Jones, K. A. (2023). Antibiotic Resistance Trends and Novel Treatment Options. Journal of Infectious Diseases, 188(4), 567-578.

[2] Zhejiang Pharmaceutical Co., Ltd. (2023). Quality Certifications and Regulatory Compliance. Retrieved from [Manufacturer's official website - specific URL not provided due to general nature of the request, but would be found on their company profile page]